CDK8 and myelodysplastic syndrome: To the best of our knowledge, the most advanced CDK8 inhibitor is SEL120, which is being investigated in phase I studies for the treatment of AML and High-risk Myelodysplastic Syndrome (HR-MDS) (NCT04021368) [29].